Details for Patent: 8,080,530

Which drugs does patent 8,080,530 protect, and when does it expire?

Patent 8,080,530 protects SOOLANTRA and is included in one NDA.

This patent has thirty-two patent family members in twenty-three countries.

Summary for Patent: 8,080,530

Title:	Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Abstract:	Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.
Inventor(s):	Manetta; Vincent (Bordertown, NJ), Watkins; Gary R. (Piscataway, NJ)
Assignee:	Galderma S.A. (Cham, CH)
Application Number:	12/468,287
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,080,530
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 8,080,530

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Galderma Labs Lp	SOOLANTRA	ivermectin	CREAM;TOPICAL	206255-001	Dec 19, 2014	AB	RX	Yes	Yes			Y			TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.

Foreign Priority and PCT Information for Patent: 8,080,530

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	03 05048	Apr 24, 2003

International Family Members for US Patent 8,080,530

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1620113		C300756	Netherlands
European Patent Office	1620113		CA 2015 00045	Denmark
European Patent Office	1620113		PA2015033	Lithuania